Oxymetazoline

Rebound congestion

Rebound congestion, or rhinitis medicamentosa, may occur. A 2006 review of the pathology of rhinitis medicamentosa concluded that use of oxymetazoline for more than three days may result in rhinitis medicamentosa and recommended limiting use to three days.[12]

Nosebleeds

Although oxymetazoline can be used for treatment of nosebleeds, it can also cause them under certain conditions, especially when nasal passages are dry. Oxymetazoline is a nasal decongestant that constricts blood vessels in the nasal mucosa, thereby reducing swelling and improving airflow. However, its use can lead to dryness and irritation of the nasal lining, which can increase the likelihood of nosebleeds.

Australian regulatory submission

Novartis recommended a five day maximum usage period, rather than three days, in a submission to the Therapeutic Goods Administration. Novartis suggested that "the justification [for 3 days] was not based on evidence," cited an extensive body of evidence, and noted a range of recommended periods from five to ten days, which coincides with the typical duration of the common cold.[13]

Pharmacodynamics

Oxymetazoline is a sympathomimetic that selectively agonizes α1 and, partially, α2 adrenergic receptors.[14] Since vascular beds widely express α1 receptors, the action of oxymetazoline results in vasoconstriction. In addition, the local application of the drug also results in vasoconstriction due to its action on endothelial postsynaptic α2 receptors; systemic application of α2 agonists, in contrast, causes vasodilation because of centrally-mediated inhibition of sympathetic tone via presynaptic α2 receptors.[15] Vasoconstriction of vessels results in relief of nasal congestion in two ways: first, it increases the diameter of the airway lumen; second, it reduces fluid exudation from postcapillary venules.[16] It can reduce nasal airway resistance (NAR) up to 35.7% and reduce nasal mucosal blood flow up to 50%.[17]

When used for treating acquired blepharoptosis, oxymetazoline is believed to work by stimulating the α1 and α2 adrenergic receptors of Müller's muscle, which helps to lift the eyelid and improve vision.[11]

Pharmacokinetics

Since imidazolines are sympathomimetic agents, their primary effects appear on α adrenergic receptors, with little if any effect on β adrenergic receptors.[18] Like other imidazolines, Oxymetazoline is readily absorbed orally.[18] Effects on α receptors from systemically absorbed oxymetazoline hydrochloride may persist for up to 7 hours after a single dose.[19] The elimination half-life in humans is 5–8 hours.[20] It is excreted unchanged both by the kidneys (30%) and in feces (10%).[19]

Brand names

Brand names for Oxymetazoline include Afrin, ClariClear, Dristan, Drixine, Drixoral, Nasivin, Nasivion, Nezeril, Nostrilla, Logicin, Vicks Sinex, Visine L.R., Sudafed OM, Otrivin, Oxy, SinuFrin, Vicks Sinex Severe (Spray), and Mucinex Sinus-Max. A topical cream formulation is sold under the brand name Rhofade.[22] Oxymetazoline ophthalmic solution for the treatment of acquired blepharoptosis is marketed as Upneeq.[10][11]

In the United Arab Emirates

oxymetazoline nasal sprays are sold under imported brand names such as Otrivin. The UAE does not manufacture oxymetazoline locally; however, domestic pharmaceutical companies such as Julphar produce xylometazoline, a structurally related imidazoline decongestant[23]

Hair loss

A topical formulation of oxymetazoline, with the developmental code name DA-020, is under development for the treatment of alopecia (hair loss).[24] As of March 2026, it is in the preclinical research stage of development for this indication.[24] The drug is being developed by Safety Shot.[24]